Value Assessment Modelling of Fingenious® Recall Service for Clinical Trials



Background and Objective


- Clinical trial success requires efficient patient recruitment.
- The Finnish Biobank Cooperative provides Fingenious® digital portal.
- Through Fingenious®, biobank samples and data are available.
- Fingenious® also enables patient recall into suitable clinical trials.
- Objective was to assess value generated by recall service. The therapy life cycle was modelled from the first patient trial to patent expiry.

Method

• The PICOSTEPS* framework was applied in the value assessment model.

Results and Conclusions

- The value added by patient recall service amounts to 47,254,964€ or 551.05 QALYs.
- The results are relevant for decision-makers considering the value gained through clinical studies in Finland.
- Future research will demonstrate the performance of the patient recall service. Value assessment modelling can be developed according to those results.
- The patient recall service has potential to gain significant value for patients, pharma companies, and society.



Authors: Roope Metsä¹, Tuomas Lundström¹, Marco Hautalahti², Christian Asseburg¹, Johanna Mäkelä², Pauli Wihuri², Erkki Soini¹ ¹ESiOR Oy, Kuopio, Finland, ²FINBB, Turku, Finland.

Contact author: Erkki Soini, ESiOR Oy, Tulliportinkatu 2 LT4, 70100 Kuopio, Finland. Email erkki.soini@esior.fi. Tel +358400533971. www.esior.fi
Fingenious contact: Johanna Mäkelä. Email johanna.makela@finbb.fi. www.fingenious.fi

^{*)}Patients-Intervention-Comparator-Outcomes-Setting-Time-Effects-Perspective-Sensitivity analysis